Anthony Rotunno
As a founding member of Lykan Bioscience, Tony aims to revolutionize the Cell Therapy industry by bringing his expertise in value creation to Lykan’s full range of development and manufacturing services for cell-based therapies.
A seasoned industry veteran with more than 40 years of biologics manufacturing experience, Tony’s successes include turning top-heavy, inefficient operations into profitable organizations as well as multiple plant builds and successful acquisitions. His experience spans both biopharmaceutical and contract manufacturing organizations including WelGen, Pharmachem, Dendreon, Lonza/Cambrex, and Marathon Biopharmaceuticals.
While at Dendreon (2010), Mr. Rotunno was instrumental in recreating Dendreon’s Provenge® operations which included the startup, commissioning, and validation of two new facilities and reducing cost of goods by approximately 80% over a 5-year period.
At Marathon, Tony guided the team in launching the manufacturing operations for the first genetically engineered recombinant /transgenic antithrombin (ATryn™) moving the company from net losses to the production of multiple generations of biologics and generating $100 million in revenue.
